<code id='A609CC17BC'></code><style id='A609CC17BC'></style>
    • <acronym id='A609CC17BC'></acronym>
      <center id='A609CC17BC'><center id='A609CC17BC'><tfoot id='A609CC17BC'></tfoot></center><abbr id='A609CC17BC'><dir id='A609CC17BC'><tfoot id='A609CC17BC'></tfoot><noframes id='A609CC17BC'>

    • <optgroup id='A609CC17BC'><strike id='A609CC17BC'><sup id='A609CC17BC'></sup></strike><code id='A609CC17BC'></code></optgroup>
        1. <b id='A609CC17BC'><label id='A609CC17BC'><select id='A609CC17BC'><dt id='A609CC17BC'><span id='A609CC17BC'></span></dt></select></label></b><u id='A609CC17BC'></u>
          <i id='A609CC17BC'><strike id='A609CC17BC'><tt id='A609CC17BC'><pre id='A609CC17BC'></pre></tt></strike></i>

          Home / hotspot / leisure time

          leisure time


          leisure time

          author:entertainment    Page View:22646
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In